본문 바로가기
KERD
논문KCI 등재

유럽의 백신 유익성-위해성 감시를 위한 ADVANCE 프로젝트 소개

An introduction of the Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) Project

김희진|김민주|최남경|이해인|정나영
한국보건정보통계학회 (The Korean Society of Health informatics statistics)|2021.11|보건정보통계학회지 (Journal of Health Informatics and Statistics)|제46권 제4호|pp. 369-377|DOI 10.21032/jhis.2021.46.4.369

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

EuropeVaccineReal-world evidencePost-marketing surveillanceBenefit-risk

초록

The vaccine benefit-risk assessment entails comprehensive and systematic evaluation of the major benefits and risks of vaccine based on information after a marketing authorization. In 2009, the influenza A (H1N1) pandemic led to the licensing of new H1N1 vaccines in many countries including Europe. The post-marketing evaluation and monitoring of H1N1 vaccines was carried out based on a project previously conducted in Europe. In 2013, the Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) project was launched with the support of Innovative Medicines Initiative (IMI) to address the limitations reported in the previous project. ADVANCE consisted of seven Work Packages (WPs), each indicating the vaccine benefitrisk monitoring readiness across four areas: Governance, Data source, Methods, and Study. First, a model for vaccine surveillance and governance with various functions such as decision making, quality management, execution, and financial administration was established. Also, the project developed a tool to identify, collect, and link the data sources available for vaccine surveillance. In addition, various methodologies were reviewed to assess the infectious disease burden, vaccine coverage, and benefit-risk based on linked data sources in Europe. Guidelines were proposed for real-world vaccine surveillance studies. Accordingly, a variety of tools and programs were developed, including a code of conduct related to the benefit-risk assessment of vaccines, ADVANCE International Research Readiness (AIRR), CodeMapper, and VaccO. Since the end of the ADVANCE project in 2019, the Vaccine Monitoring Collaboration for Europe (VAC4EU) has been conducting effective and sustainable vaccine benefit-risk monitoring programs based on the vision and ideology of ADVANCE. This study explains the contents and findings of ADVANCE with emphasis on WPs and proposes directions for establishing a vaccine benefit-risk assessment system in Korea.

Abstract

The vaccine benefit-risk assessment entails comprehensive and systematic evaluation of the major benefits and risks of vaccine based on information after a marketing authorization. In 2009, the influenza A (H1N1) pandemic led to the licensing of new H1N1 vaccines in many countries including Europe. The post-marketing evaluation and monitoring of H1N1 vaccines was carried out based on a project previously conducted in Europe. In 2013, the Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) project was launched with the support of Innovative Medicines Initiative (IMI) to address the limitations reported in the previous project. ADVANCE consisted of seven Work Packages (WPs), each indicating the vaccine benefitrisk monitoring readiness across four areas: Governance, Data source, Methods, and Study. First, a model for vaccine surveillance and governance with various functions such as decision making, quality management, execution, and financial administration was established. Also, the project developed a tool to identify, collect, and link the data sources available for vaccine surveillance. In addition, various methodologies were reviewed to assess the infectious disease burden, vaccine coverage, and benefit-risk based on linked data sources in Europe. Guidelines were proposed for real-world vaccine surveillance studies. Accordingly, a variety of tools and programs were developed, including a code of conduct related to the benefit-risk assessment of vaccines, ADVANCE International Research Readiness (AIRR), CodeMapper, and VaccO. Since the end of the ADVANCE project in 2019, the Vaccine Monitoring Collaboration for Europe (VAC4EU) has been conducting effective and sustainable vaccine benefit-risk monitoring programs based on the vision and ideology of ADVANCE. This study explains the contents and findings of ADVANCE with emphasis on WPs and proposes directions for establishing a vaccine benefit-risk assessment system in Korea.

참고문헌 (38)

  1. 정소현, "국내외 의약품 유익성-위해성 평가 기법에 대한 고찰", 약 학 회 지, 63(2), pp.103~112 (2019), 대한약학회[DOI]
  2. Lee EK, "Evidence-based benefit-risk assessment of medication", J Health Tech Assess, 1, pp.22~26 (2013)
  3. Ledent E, "Post-marketing benefit-risk assessment of rotavirus vaccination in Japan : a simulation and modelling analysis", Drug Saf, 39(3), pp.219~230 (2016)[DOI]
  4. Chen RT, "Enhancing vaccine safety capacity globally : A lifecycle perspective", Am J Prev Med, 49(6 Suppl 4), pp.S364~S376 (2015)[DOI]
  5. Sturkenboom M, "Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines", Vaccine, 38(Suppl 2), pp.B1~B7 (2020)[DOI]
  6. Kurz X, "The ADVANCE Code of Conduct for collaborative vaccine studies", Vaccine, 35(15), pp.1844~1855 (2017)[DOI]
  7. "VAccine monitoring Collaboration for Europe (VAC4EU)"[URL]
  8. Bollaerts K, "Benefitrisk monitoring of vaccines using an interactive dashboard : a methodological proposal from the ADVANCE Project", Drug Saf, 41(8), pp.775~786 (2018)[DOI]
  9. ADVANCE, "Deliverable 3.5. Procedures for data access, sharing, linkage and integration, including privacy and ethics", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  10. ADVANCE, "Catalogue and meta-profiles of data sources for vaccine benefit- risk monitoring", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2016)
  11. ADVANCE, "Deliverable 1.10. Final conceptual models for public-private interaction", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2016)
  12. "Accelerated Development of VAccine beNefit-risk Collaboration in Europe" (2018)[URL]
  13. ADVANCE, "Deliverable 1.13. Accelerated Development of VAccine beNefit-risk Collaboration in Europe", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  14. Torcel-Pagnon L, "Guidance for the governance of public-private collaborations in vaccine post-marketing settings in Europe", Vaccine, 37(25), pp.3278~3289 (2019)[DOI]
  15. ADVANCE, "Deliverable 1.9. Best practice and code of conduct for benefit-risk monitoring of vaccines", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2016)
  16. ADVANCE, "Deliverable 1.12 Developing communication strategies on vaccine benefits and risks: Guidance for public-private collaborations", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  17. ADVANCE, "Deliverable 2.4 Final report on landscape analysis, synergies, added value of synergies for ADVANCE and future opportunities", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  18. ADVANCE, "Deliverable 4.9 Work Package 4 White Paper: methods for vaccine benefit-risk monitoring, including vaccine coverage, safety and effectiveness", Accelerated Development of VAccine beNefitrisk Collaboration in Europe (ADVANCE), ~ (2017)
  19. ADVANCE, "Deliverable 4.1. Report on appraisal of methods for vaccine coverage, burden of disease and vaccine benefits", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2014)
  20. ADVANCE, "Deliverable 4.2. Report on appraisal of vaccine safety methods", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2014)
  21. ADVANCE, "Deliverable 4.3. Report on appraisal of vaccine benefit-risk methodology", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2014)
  22. ADVANCE, "Deliverable 5.4. Fingerprinting of the participating health care databases", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2019)
  23. ADVANCE, "Deliverable 5.6. Results of POC-phase 1 studies", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  24. Sturkenboom M, "ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations", Vaccine, 38(Suppl 2), pp.B8~B21 (2020)[DOI]
  25. ADVANCE, "Deliverable 5.7. Proof-of-Concept studies Phase 1: Results on near real-time monitoring", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2019)
  26. Emborg HD, "ADVANCE system testing : Can coverage of pertussis vaccination be estimated in European countries using electronic healthcare databases : an example", Vaccine, 38(Suppl 2), pp.B22~B30[DOI]
  27. Bollaerts K, "ADVANCE system testing : Benefit-risk analysis of a marketed vaccine using multi-criteria decision analysis and individual-level state transition modelling", Vaccine, 38(Suppl 2), pp.B65~B75 (2020)[DOI]
  28. Weibel D, "ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination", Vaccine, 38(Suppl 2), pp.B38~B46 (2020)[DOI]
  29. Htar MTT, "Advance system testing : Vaccine benefit studies using multi-country electronic health data-The example of pertussis vaccination", Vaccine, 38(Suppl 2), pp.B31~B37 (2020)[DOI]
  30. Bollaerts K, "ADVANCE: Towards near real-time monitoring of vaccination coverage, benefits and risks using European electronic health record databases", Vaccine, 38(Suppl 2), pp.B76~B83 (2019)[DOI]
  31. ADVANCE, "Deliverable 7.7. Implementability analysis Blueprint of a framework to rapidly provide scientific evidence on post-marketing vaccination benefits and risks for informed decisions", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2018)
  32. Becker BFH, "CodeMapper : semiautomatic coding of case definitions. A contribution from the ADVANCE project", Pharmacoepidemiol Drug Saf, 26(8), pp.998~1005 (2017)[DOI]
  33. Avillach P, "A semantic approach for the homogeneous identification of events in eight patient databases : a contribution to the European eu-ADR project", Stud Health Technol Inform, 150, pp.190~194 (2009)[DOI]
  34. ADVANCE, "Deliverable 5.5. Ontology for the Integration and Extraction of Vaccine-related Information in Europe: a proof of concept", Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE), ~ (2017)
  35. "COVID-19-vaccine-monitoring"[URL]
  36. Final report: Feasibility analysis of an EU infrastructure for COVID-19 vaccine monitoring, "Sturkenboom M", VAC4EU, ~ (2021)
  37. Petousis-Harris H, "Assessing the safety of COVID-19 vaccines : a primer", Drug Saf, 43(12), pp.1205~1210 (2020)[DOI]
  38. "Guidelines for Periodic Benefit-Risk Evaluation Report (PBRER)" (2014)[URL]

관련 논문AI추천

외국의 백신 능동적 감시 시스템 소개박상신, 임은선, 정나영, 최남경한국보건정보통계학회 · 보건정보통계학회지2019 · 제44권 제4호Vaccine Safety Datalink를 통한 백신 안전성 평가: 연구 기여에 대한 종합적 검토원희현, 임은선, 정나영, 최남경한국보건정보통계학회 · 보건정보통계학회지2025 · 제50권 제2호설문조사를 통한 전문가 대상 예방접종 후 이상반응 관련 우선순위 연구주제 선정 기준모델 제시김주환, 김현정, 노윤하, 신주영, 윤동원, 이혜성한국임상약학회 · 한국임상약학회지2019 · 제29권 제3호미국, 일본, 유럽의 의약품 생애주기 데이터 구축 및 활용 현황김소영, 박종혁, 양희수한국보건정보통계학회 · 보건정보통계학회지2023 · 제48권 제2호백신제제 안전 사용 정보지 마련을 위한 연구노혜진, 박지은, 신완균, 오정미, 이혜숙, 지은희, 한나영, 홍진이한국임상약학회 · 한국임상약학회지2010 · 제20권 제1호Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005–2017김주환, 신주영, 윤동원, 이혜성연세대학교의과대학 · Yonsei Medical Journal2020 · 제61권 제7호

이 간행물의 다른 논문 (9건)

한국 고등학생들의 식이습관 및 체질량지수와 구강질환증상경험의 관련성-2019년도 제15차 청소년건강행태온라인조사를 중심으로정선락, 장지언pp. 378-384치과위생사의 보수교육 참여도와 면허신고제 인식수준의 관련성송근배, 김건엽, 최연희, 이혜영pp. 385-392COVID-19 대유행으로 인한 대구시민의 신체활동 변화와 영향요인김건엽, 진수희pp. 393-401대학생의 생활습관 요인과 비만과의 상관성: 경기도 지역 1개 대학교를 중심으로박혜자, 정진희pp. 402-409시군구 지역별 성인의 비만율 차이 및 영향요인김봉정pp. 410-419
원문 보기